The FDA approved Garzulys, an insulin aspart biosimilar, adding another entrant to the competitive landscape that is slowly deflating insulin list prices. The approval marks the latest step in the biosimilar wave that has been building since the Inflation Reduction Act's insulin cap provisions took effect. [1]

The gap between the announcement's routine framing and the structural shift it represents is the divergence. Each new biosimilar entry increases competitive pressure on list prices — but the diabetes community on X treats the approvals as incremental rather than transformative, citing PBM rebate structures that blunt the price competition's impact on out-of-pocket costs. [1]

For patients, the question is whether the growing biosimilar market translates into lower copays or simply generates rebate revenue for pharmacy benefit managers. The list-price reductions that biosimilar competition produces may not reach the patients who need them most if the rebate system intercepts the savings. [1]

The approval is one data point in a larger trend: the insulin market is becoming more competitive at the manufacturing level while remaining opaque at the patient level. Garzulys enters a market where the supply side is increasingly crowded but the pricing side remains governed by intermediaries rather than competition. [1]